Quantitative proteomics identifies activation of hallmark pathways of cancer in patient melanoma

Journal of Proteomics and Bioinformatics

Volumn 6, Issue 3, 2013, Pages 043-050

  Byrum, Stephanie D ^a   Larson, Signe K ^a   Avaritt, Nathan L ^a   Moreland, Linley E ^a   Mackintosh, Samuel G ^a   Cheung, Wang L ^b   Tackett, Alan J ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b ORLANDO HEALTH   (United States)

Author keywords

FFPE tissue; Mass spectrometry; Melanoma; Proteomics; Quantitative

Indexed keywords

DECORIN; FERRITIN; INITIATION FACTOR 4A; LUMICAN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; MOESIN; PROTHYMOSIN ALPHA; THYMOSIN BETA10;

APOPTOSIS; ARTICLE; BENIGN TUMOR; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CELL ADHESION; CELL JUNCTION; CELL MOTILITY; CELL PROLIFERATION; DOWN REGULATION; EXTRACELLULAR MATRIX; HUMAN; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MELANOCYTE; MELANOCYTIC NEVUS; MELANOMA; METASTATIC MELANOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TISSUE SECTION; UPREGULATION;

EID: 84876160986     PISSN: None     EISSN: 0974276X     Source Type: Journal    
DOI: 10.4172/jpb.1000260     Document Type: Article

References (60)

1. Metz B, Kersten GF, Hoogerhout P, Brugghe HF, Timmermans HA, et al. (2004) Identifcation of formaldehyde-induced modifcations in proteins: reactions with model peptides. J Biol Chem 279: 6235-6243.
2. Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, et al. (2007) Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc 82: 364-380.
3. ACS (2012) Cancer Facts and Figures 2012. Atlanta: American Cancer Society.
4. Helmbach H, Rossmann E, Kern MA, Schadendorf D (2001) Drug-resistance in human melanoma. Int J Cancer 93: 617-622.
5. Soengas MS, Lowe SW (2003) Apoptosis and melanoma chemoresistance. Oncogene 22: 3138-3151.
6. Sabel MS, Liu Y, Lubman DM (2011) Proteomics in Melanoma Biomarker Discovery: Great Potential, Many Obstacles. Int J Proteomics.
7. Huang SK, Darfer MM, Nicholl MB, You J, Bemis KG, et al. (2009) LC/MS-based quantitative proteomic analysis of paraffn-embedded archival melanomas reveals potential proteomic biomarkers associated with metastasis. PLoS One 4: e4430.
8. Rezaul K, Murphy M, Lundgren DH, Wilson L, Han DK (2010) Combined mass spectrometry- and immunohistochemistry-based approach to determine protein expression in archival melanoma--proof of principle. Pigment Cell Melanoma Res 23: 849-852.
9. Byrum S, Avaritt NL, Mackintosh SG, Munkberg JM, Badgwell BD, et al. (2011) A quantitative proteomic analysis of FFPE melanoma. J Cutan Pathol 38: 933-936.
10. Pontén F, Jirström K, Uhlen M (2008) The Human Protein Atlas--a tool for pathology. J Pathol 216: 387-393.
11. Byrum S, Mackintosh SG, Edmondson RD, Cheung WL, Taverna SD, et al. (2011) Quantitative Analysis of Histone Exchange during Chromatin Purifcation. J Integr OMICS 1: 61-65.
12. Byrum SD, Taverna SD, Tackett AJ (2011) Quantitative analysis of histone exchange for transcriptionally active chromatin. J Clin Bioinforma 1: 17.
13. Zybailov B, Mosley AL, Sardiu ME, Coleman MK, Florens L, et al. (2006) Statistical analysis of membrane proteome expression changes in Saccharomyces cerevisiae. J Proteome Res 5: 2339-2347.
14. Chaerkady R, Pandey A (2007) Quantitative proteomics for identifcation of cancer biomarkers. Proteomics Clin Appl 1: 1080-1089.
15. Schulze WX, Usadel B (2010) Quantitation in mass-spectrometry-based proteomics. Annu Rev Plant Biol 61: 491-516.
16. Wu Q, Zhao Q, Liang Z, Qu Y, Zhang L, et al. (2012) NSI and NSMT: usages of MS/MS fragment ion intensity for sensitive differential proteome detection and accurate protein fold change calculation in relative label-free proteome quantifcation. Analyst 137: 3146-3153.
17. Stekel D (2003) Microarray Bioinformatics. Cambridge University Press, New York.
18. Draghici S, Khatri P, Tarca AL, Amin K, Done A, et al. (2007) A systems biology approach for pathway level analysis. Genome Res 17: 1537-1545.
19. Pellinen T, Arjonen A, Vuoriluoto K, Kallio K, Fransen JA, et al. (2006) Small GTPase Rab21 regulates cell adhesion and controls endosomal traffc of beta1-integrins. J Cell Biol 173: 767-780.
20. Krishnan V, Bane SM, Kawle PD, Naresh KN, Kalraiya RD (2005) Altered melanoma cell surface glycosylation mediates organ specifc adhesion and metastasis via lectin receptors on the lung vascular endothelium. Clin Exp Metastasis 22: 11-24.
21. Ji H, Chang EY, Lin KY, Kurman RJ, Pardoll DM, et al. (1998) Antigen-specifc immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int J Cancer 78: 41-45.
22. Chan CC, Dostie J, Diem MD, Feng W, Mann M, et al. (2004) eIF4A3 is a novel component of the exon junction complex. RNA 10: 200-209.
23. Xia Q, Kong XT, Zhang GA, Hou XJ, Qiang H, et al. (2005) Proteomics-based identifcation of DEAD-box protein 48 as a novel autoantigen, a prospective serum marker for pancreatic cancer. Biochem Biophys Res Commun 330: 526-532.
24. Kanehisa M, Goto S (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28: 27-30.
25. Somasundaram R, Herlyn M (2012) Melanoma exosomes: messengers of metastasis. Nat Med 18: 853-854.
26. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, et al. (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635-3648.
27. Halaban R, Funasaka Y, Lee P, Rubin J, Ron D, et al. (1991) Fibroblast growth factors in normal and malignant melanocytes. Ann N Y Acad Sci 638: 232-243.
28. Hemesath TJ, Price ER, Takemoto C, Badalian T, Fisher DE (1998) MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature 391: 298-301.
29. Dai DL, Martinka M, Li G (2005) Prognostic signifcance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol 23: 1473-1482.
30. Erhardt P, Schremser EJ, Cooper GM (1999) B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol Cell Biol 19: 5308-5315.
31. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
32. Jiang Y, Ma W, Wan Y, Kozasa T, Hattori S, et al. (1998) The G protein G alpha12 stimulates Bruton's tyrosine kinase and a rasGAP through a conserved PH/BM domain. Nature 395: 808-813.
33. Uribe P, Andrade L, Gonzalez S (2006) Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. J Invest Dermatol 126: 161-166.
34. Cohen C, Zavala-Pompa A, Sequeira JH, Shoji M, Sexton DG, et al. (2002) Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res 8: 3728-3733.
35. Yajima I, Kumasaka MY, Thang ND, Goto Y, Takeda K, et al. (2012) RAS/RAF/ MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy. Dermatol Res Pract 2012: 354191.
36. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y (2006) The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 203: 1651-1656.
37. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J (2003) NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 9: 6483-6488.
38. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, et al. (2004) PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30: 193-204.
39. Proctor PH, McGinness JE (1986) The function of melanin. Arch Dermatol 122: 507-508.
40. Hill HZ (1992) The function of melanin or six blind people examine an elephant. Bioessays 14: 49-56.
41. Ruiter D, Bogenrieder T, Elder D, Herlyn M (2002) Melanoma-stroma interactions: structural and functional aspects. Lancet Oncol 3: 35-43.
42. Arosio P, Ingrassia R, Cavadini P (2009) Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta 1790: 589-599.
43. Harrison PM, Arosio P (1996) The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1275: 161-203.
44. Baldi A, Lombardi D, Russo P, Palescandolo E, De Luca A, et al. (2005) Ferritin contributes to melanoma progression by modulating cell growth and sensitivity to oxidative stress. Clin Cancer Res 11: 3175-3183.
45. Pham CG, Bubici C, Zazzeroni F, Papa S, Jones J, et al. (2004) Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 119: 529-542.
46. Jiang X, Kim HE, Shu H, Zhao Y, Zhang H, et al. (2003) Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science 299: 223-226.
47. Ioannou K, Samara P, Livaniou E, Derhovanessian E, Tsitsilonis OE (2012) Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy. Cancer Immunol Immunother 61: 599-614.
48. Klein RM, Aplin AE (2009) Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions. Cancer Res 69: 2224-2233.
49. Gaggioli C, Sahai E (2007) Melanoma invasion - current knowledge and future directions. Pigment Cell Res 20: 161-172.
50. Kovacs EM, Makar RS, Gertler FB (2006) Tuba stimulates intracellular N-WASP-dependent actin assembly. J Cell Sci 119: 2715-2726.
51. Nakahara H, Otani T, Sasaki T, Miura Y, Takai Y, et al. (2003) Involvement of Cdc42 and Rac small G proteins in invadopodia formation of RPMI7951 cells. Genes Cells 8: 1019-1027.
52. Yu FX, Lin SC, Morrison-Bogorad M, Atkinson MA, Yin HL (1993) Thymosin beta 10 and thymosin beta 4 are both actin monomer sequestering proteins. J Biol Chem 268: 502-509.
53. Liu CR, Ma CS, Ning JY, You JF, Liao SL, et al. (2004) Differential thymosin beta-10 expression levels and actin flament organization in tumor cell lines with different metastatic potential. Chin Med J (Engl) 117: 213-218.
54. Weterman MA, van Muijen GN, Ruiter DJ, Bloemers HP (1993) Thymosin beta-10 expression in melanoma cell lines and melanocytic lesions: a new progression marker for human cutaneous melanoma. Int J Cancer 53: 278-284.
55. Ilmonen S, Jahkola T, Turunen JP, Muhonen T, Asko-Seljavaara S (2004) Tenascin-C in primary malignant melanoma of the skin. Histopathology 45: 405-411.
56. Furthmayr H, Lankes W, Amieva M (1992) Moesin, a new cytoskeletal protein and constituent of flopodia: its role in cellular functions. Kidney Int 41: 665-670.
57. Estecha A, Sánchez-Martín L, Puig-Kröger A, Bartolomé RA, Teixidó J, et al. (2009) Moesin orchestrates cortical polarity of melanoma tumour cells to initiate 3D invasion. J Cell Sci 122: 3492-3501.
58. De Luca A, Santra M, Baldi A, Giordano A, Iozzo RV (1996) Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J Biol Chem 271: 18961-18965.
59. Vuillermoz B,Khoruzhenko A,D'Onofrio MF,Ramont L,Venteo L,et al. (2004) The small leucine-rich proteoglycan lumican inhibits melanoma progression. Exp Cell Res 296: 294-306.
60. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-925.